The Cambridge Probiotic/Antibiotic Trial 1
This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group
1. Total numbers of facultative anaerobes:
– significantly increased in the patients on antibiotics and placebo at the end of the antibiotic treatment (*P<0.05) and remained increased post antibiotic therapy (*P<0.05) (Group 1).
– significantly increased in the patients on antibiotics and placebo at the end of the antibiotic treatment (*P<0.05), but the numbers decreased significantly after introducing Lab4 probiotic supplementation post antibiotic (*P<0.05, Group 2).
– remained stable in the patients on antibiotics and Lab4 probiotics throughout the study period (Group 3).
2. Lab4 probiotic supplementation reduced the overgrowth population of coliforms, enterococci and staphylococci in the re-growth microbiota following antibiotic therapy.